 Bcl-2/IgH rearrangements can be quantified in follicular lymphoma (FL) from peripheral blood (PB) by polymerase chain reaction (PCR).     ///    A positive posttreatment Bcl-2/IgH status was associated with shorter PFS (8.7 months vs not reached.     ///    "At inclusion, 114 patients (66%) tested positive and 59 (34%) were negative for Bcl-2/IgH. "    ///    Our data suggest that pre- and posttreatment Bcl-2/IgH levels from PB have significant prognostic value for PFS in FL patients receiving first-line immunochemotherapy.     ///    Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy..     ///    "We therefore prospectively studied PB Bcl-2/IgH levels from 173 first-line FL patients who were consecutively enrolled, randomized, and treated within the multicenter phase 3 clinical trial NHL1-2003 comparing bendamustine-rituximab (B-R) with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone. "    ///    No PFS difference between treatment arms was observed in Bcl-2/IgH-positive patients.     ///    The prognostic value of Bcl-2/IgH levels in FL remains controversial.     ///    "High pretreatment Bcl-2/IgH levels had an adverse effect on progression-free survival (PFS) compared with intermediate or low levels (high vs intermediate: hazard [HR], 4.28. "    ///    "By multivariate analysis, the pretreatment Bcl-2/IgH level was the strongest predictor for PFS. "